Furthermore, the clinical relevance of the hypothesized role of chemerin as a biomarker for the weight loss-induced amelioration of liver integrity remains to be validated by studies involving cohorts with a higher proportion of patients with fibrosis or hepatic malfunction. This evidence concerns the gene RARRES2 and fibrosis.